Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.

Details

Ressource 1Request a copy Under indefinite embargo.
UNIL restricted access
State: Public
Version: Final published version
License: Not specified
Serval ID
serval:BIB_30CD844F1841
Type
Article: article from journal or magazin.
Collection
Publications
Institution
UNIL/CHUV
Title
Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.
Journal
Clinical microbiology and infection
Author(s)
Girardin F., Manuel O., Marzolini C., Buclin T.
ISSN
1469-0691 (Electronic)
ISSN-L
1198-743X
Publication state
Published
Issued date
08/2022
Peer-reviewed
Oui
Volume
28
Number
8
Pages
1044-1046
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Keywords
Antiviral Agents/therapeutic use, Drug Interactions, Humans, Ritonavir/pharmacokinetics, Ritonavir/therapeutic use, SARS-CoV-2, COVID-19 Drug Treatment, Antivirals, COVID-19, Drug safety, Drug-drug interactions, Nirmatrelvir, Pharmacokinetic boosters, Ritonavir
URN
urn:nbn:ch:serval-BIB_30CD844F18415
OAI-PMH
oai:serval.unil.ch:BIB_30CD844F1841
DOI
10.1016/j.cmi.2022.03.030
Pubmed
35358684
Web of science
000855302300003
Open Access
Yes
Create date
11/04/2022 8:17
Last modification date
06/08/2024 6:02
Usage data